Anti-Hu CD74 Purified

Anti-Hu CD74 Purified
Regulatory status
RUO
Antigen
CD74
Clone
LN2
Format
Purified
Reactivity
Human
Variant
0.1 mg
11-500-C100
In stock
140.00 USD
Variant
0.1 mg
11-261-C100
In stock
140.00 USD
Product details
Description
Images
References
Isotype
Mouse IgG1
Specificity
The antibody LN2 recognizes an extracellular epitope of CD74 (the MHC II-associated invariant chain, Ii), a type II transmembrane protein expressed in antigen-presenting cells, as well as e.g. on activated neoplastic cells in T cell lymphomas, in lymph node germinal center, mantle zone B cells, histiocytes, interdigitating reticulum cells, Langerhans cells, thymic dendritic cells and peripheral blood B lymphocytes.
Workshop
HLDA IV: WS Code B 129; HLDA V: WS Code B CD74.3
Application details
Flow cytometry: Recommended dilution: 2-5 μg/ml.
Reactivity
Human
Immunogen
SU-DHL-4 lymphoma cells
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
p33, DHLAG, HLADG, Ia-gamma
Antigen description
CD74 (the MHC II-associated invariant chain, Ii) is a type II transmembrane protein expressed in antigen-presenting cells, that serves as MHC II chaperone which promotes MHC II trafficking from the ER to endocytic compartments, prevents peptide binding in the ER and contributes to peptide editing in the MHC II compartment; it is also an accessory signaling molecule implicated e.g. in malignant B cell proliferation. Stimulation of cell surface CD74 leads to NFkappaB activation, which enables entry of the stimulated cell into the S phase. CD74 binds pro-inflammatory cytokine MIF with high affinity and interacts with CD44. Binding of Vpu, an HIV1 protein, to CD74 modulates MHC II presentation.
Entrez Gene ID 972
UniProt ID P04233
11-500_FC_Profil značení
Flow cytometry surface staining pattern of human peripheral whole blood stained using anti-human CD74 (LN2) purified antibody (concentration in sample 1,7 μg/ml, GAM APC).
11-500_FC_Histogram
Separation of human CD74 positive lymphocytes (red-filled) from CD74 negative lymphocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD74 (LN2) purified antibody (concentration in sample 1,7 μg/ml, GAM APC).

General references:

Hussain A, Wesley C, Khalid M, Chaudhry A, Jameel S: Human immunodeficiency virus type 1 Vpu protein interacts with CD74 and modulates major histocompatibility complex class II presentation. J Virol. 2008 Jan;82(2):893-902.
PubMed
Gore Y, Starlets D, Maharshak N, Becker-Herman S, Kaneyuki U, Leng L, Bucala R, Shachar I: Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem. 2008 Feb 1;283(5):2784-92.
PubMed
Lantner F, Starlets D, Gore Y, Flaishon L, Yamit-Hezi A, Dikstein R, Leng L, Bucala R, Machluf Y, Oren M, Shachar I: CD74 induces TAp63 expression leading to B-cell survival. Blood. 2007 Dec 15;110(13):4303-11.
PubMed
Stein R, Mattes MJ, Cardillo TM, Hansen HJ, Chang CH, Burton J, Govindan S, Goldenberg DM: CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res. 2007 Sep 15;13(18 Pt 2):5556s-5563s.
PubMed
Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L, Becker-Herman S, Berrebi A, Shachar I: Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood. 2006 Jun 15;107(12):4807-16.
PubMed

Product specific references:

Burton JD, Ely S, Reddy PK, Stein R, Gold DV, Cardillo TM, Goldenberg DM: CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res. 2004 Oct 1;10(19):6606-11.
PubMed
Badve S, Deshpande C, Hua Z, Lögdberg L: Expression of invariant chain (CD 74) and major histocompatibility complex (MHC) class II antigens in the human fetus. J Histochem Cytochem. 2002 Apr;50(4):473-82.
PubMed
Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, Delohery T, Chen Y, Mitchell RA, Bucala R: MIF signal transduction initiated by binding to CD74. J Exp Med. 2003 Jun 2;197(11):1467-76.
PubMed
Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989).
Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
Perez MT, Cabello-Inchausti B, Castellano-Sanchez A, Kottiech S, Davila E, Willis I, Barkin J: Primary gastroesophageal-ileal hodgkin lymphoma. Arch Pathol Lab Med. 2002 Dec;126(12):1534-7.
PubMed
Freeman GJ, Cardoso AA, Boussiotis VA, Anumanthan A, Groves RW, Kupper TS, Clark EA, Nadler LM: The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor. J Immunol. 1998 Sep 15;161(6):2708-15.
PubMed
Variant
0.1 mg
11-500-C100
In stock
140.00 USD
Variant
0.1 mg
11-261-C100
In stock
140.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
200.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
60.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
50.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
0.1 mg
105.00 USD